Abstract
Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Acs P, Wang QJ, Bogi K, Marquez AM, Lorenzo PS, Biro T, Szallasi Z, Mushinski JF and Blumberg PM . (1997). J. Biol. Chem., 272, 28793–28799.
Bajusz I, Sipos L, Gyorgypal Z, Carrington EA, Jones RS, Gausz J and Gyurkovics H . (2001). Genetics, 159, 1135–1150.
Billadeau D, Jelinek DF, Shah N, LeBien TW and Van Ness B . (1995). Cancer Res., 55, 3640–3646.
Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW and Van Ness B . (1997). Cancer Res., 57, 2268–2275.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K . (2003). EMBO J., 22, 5323–5335.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y . (2002). Science, 298, 1039–1043.
Carrington EA and Jones RS . (1996). Development, 122, 4073–4083.
Chen-Kiang S . (1995). Curr. Top. Microbiol. Immunol., 194, 189–198.
Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM and Bergsagel PL . (1998). Blood, 92, 3025–3034.
Cheung WC and Van Ness B . (2001). Leukemia, 15, 264–271.
Cheung WC and Van Ness B . (2002). Leukemia, 16, 1182–1188.
Croonquist PA, Linden MA, Zhao F and Van Ness BG . (2003). Blood, 102, 2581–2592.
Czermin B, Melfi R, McCabe D, Seitz V, Imhof A and Pirrotta V . (2002). Cell, 111, 185–196.
Denisenko O, Shnyreva M, Suzuki H and Bomsztyk K . (1998). Mol. Cell. Biol., 18, 5634–5642.
Fukuyama T, Otsuka T, Shigematsu H, Uchida N, Arima F, Ohno Y, Iwasaki H, Fukuda T and Niho Y . (2000). Br. J. Haematol., 108, 842–847.
Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA and Lust JA . (1993). Cancer Res., 53, 5320–5327.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM . (2003). Proc. Natl. Acad. Sci. USA, 100, 11606–11611.
Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P and Reinberg D . (2002). Genes Dev., 16, 2893–2905.
Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE and Simon JA . (2002). Cell, 111, 197–208.
Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P and Reinberg D . (2002). Genes Dev., 16, 479–489.
Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P and Sharp PA . (2002). Nat. Med., 8, 681–686.
Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP and Meijer CJ . (2001). J. Immunol., 166, 5925–5934.
Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP and Meijer CJ . (2000). Am. J. Pathol., 157, 709–715.
Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD and Jenuwein T . (2000). Nature, 406, 593–599.
Rowley M, Liu P and Van Ness B . (2000). Blood, 96, 3175–3180.
Sears RC and Nevins JR . (2002). J. Biol. Chem., 277, 11617–11620.
Tachibana M, Sugimoto K, Fukushima T and Shinkai Y . (2001). J. Biol. Chem., 276, 25309–25317.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM . (2002). Nature, 419, 624–629.
Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP . (2001). Br. J. Haematol., 112, 950–958.
Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y and Chang C . (2001). J. Biol. Chem., 276, 40417–40423.
Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA and Jelinek DF . (1996). Leukemia, 10, 866–876.
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B and Shaughnessy Jr J . (2002). Blood, 99, 1745–1757.
Zhan F, Tian E, Bumm K, Smith R, Barlogie B and Shaughnessy Jr J . (2003). Blood, 101, 1128–1140.
Acknowledgements
We thank Dr AP Otte, University of Amsterdam, The Netherlands, for providing antibodies and reagents. We also acknowledge the assistance of Dr Mesher and Dr Shimizu at the University of Minnesota in allowing the use of specific equipment. This study was supported by grants from the National Institute of Health (PO1 CA62242), from the Multiple Myeloma Research Foundation (BVN) and the National Institute of Health Cancer Biology Training Grant CA09138 (PAC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Croonquist, P., Van Ness, B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24, 6269–6280 (2005). https://doi.org/10.1038/sj.onc.1208771
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208771
Keywords
This article is cited by
-
Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies
Cell Communication and Signaling (2024)
-
Progranulin regulates the development and function of NKT2 cells through EZH2 and PLZF
Cell Death & Differentiation (2022)
-
Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Cell Death & Disease (2021)
-
In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma
Blood Cancer Journal (2020)